with the “Double halo” of covid-19 oral medicine concept stock and new energy lithium battery concept stock, senxuan pharmaceutical’s share price soared all the way, but it was suddenly “Waterloo” by shareholders.
On February 9, senxuan pharmaceutical announced that its shareholder Tong Zhenming planned to reduce the company’s shares by up to 4.2691 million shares due to personal capital needs, accounting for 1% of the total share capital. According to the latest closing price, the total cash out amount will reach 86.2374 million yuan.
Previously, on January 28, senxuan pharmaceutical announced the lifting of the ban on shares, of which a total of 345 million shares were lifted, accounting for 80.92% of the total share capital of the company. Of which Jinghua Pharmaceutical Group Co.Ltd(002349) lifted the ban on 308 million shares, accounting for 72.31%; Tong Zhenming lifted the ban on 36.7418 million shares, accounting for 8.6%.
Or affected by this news, as of the closing on February 10, senxuan pharmaceutical’s share price closed at 20.20 yuan / share, down 9.01%, with the latest total market value of 8.624 billion yuan.
Data source:
According to tianyancha data, Tong Zhenming, as one of the top 10 shareholders of senxuan medicine, currently holds 36.7418 million shares of senxuan medicine, accounting for 8.61%. From October 2008 to March 2012, Tong Zhenming mainly served as the executive director and general manager of Jiangsu senxuan pharmaceutical and Chemical Co., Ltd; From March 2012 to now, he has served as the director and general manager of Jiangsu senxuan pharmaceutical and Chemical Co., Ltd.
In July 2020, senxuan pharmaceutical was listed on the selection layer; In November 2021, the company moved to the Beijing stock exchange, during which the share price soared. According to the data, its share price was still hovering around 6.08 yuan / share in November 2021, but by January 2022, its share price soared to 38.78 yuan / share, an increase of 84.32%.
Data source:
The soaring share price of senxuan medicine is related to the “Double halo” blessing of covid-19 oral medicine concept stocks and new energy lithium battery concept stocks.
It is reported that due to the brilliant effect of Pfizer covid-19 oral drug paxlovid, it has been authorized by FDA for emergency use. Pfizer oral medicine is a combination of pf-07321332 and ritonavir. Subsequently, its parent company Jinghua Pharmaceutical Group Co.Ltd(002349) said in the investment interactive reply that the annual production capacity of the main intermediates of senxuan pharmaceutical ritonavir currently accounts for a high share of the production capacity of such intermediates.
As it is said that it is the covid-19 oral drug raw material supplier of Pfizer, the global pharmaceutical leader, although senxuan pharmaceutical has announced that it denies the above rumors, it is still hyped by active hot money. Since 2022, senxuan pharmaceutical has been listed on the dragon and tiger list for nearly 18 times, the latest time on January 28, on the grounds that the turnover rate is 20%.
From the recent dragon and tiger list of senxuan medicine, it mainly deals in the business department of securities companies, few institutional seats are bought, and the intention of hot money relay speculation is obvious.
Then, senxuan medicine got on the “express” of new energy. It is reported that dioxane, as the chemical intermediate product of senxuan medicine, is the solvent of lithium battery electrolyte. At present, it is mainly used in the primary battery field of lithium iron phosphate route.
Recently, senxuan pharmaceutical also disclosed that the company’s annual production capacity of dioxane is 3000 tons, and the annual production capacity after expansion will reach 6000 tons. At present, the equipment installation of the expansion project has been completed and is in the stage of local commissioning. It is expected that the trial production conditions will be available before the end of December.
But it has to be said that covid-19 drug and lithium battery did save senxuan pharmaceutical’s long-term depressed share price. Although the company’s share price has been corrected recently, and the latest share price is reported at 20.20 yuan / share, which is almost halved from the higher point, its share price still increased by 136.25% compared with 8.55 yuan / share on December 24, 2021.
In addition, senxuan pharmaceutical carried out the reduction plan more than Tong Zhenming. After hitting a record high share price of 38.78 yuan / share on January 20, on that night, the company’s director Cheng Jian, director and deputy general manager Jiang Chunjuan and secretary and financial director Zhu Shizhang announced the reduction at the same time, with a reduction of no more than 25000 shares per person.
It is reported that Jiangsu Sen Xuan medicine Limited by Share Ltd (referred to as Sen Xuan medicine) is a subsidiary of Shenzhen board company Jinghua Pharmaceutical Group Co.Ltd(002349) , mainly engaged in chemical raw materials, pharmaceutical intermediates and oxygen heterocyclic chemical intermediates research and production, products include anti-tumor drugs, antipyretic, analgesic and anti-inflammatory drugs, anti-epileptic drugs, anti AIDS medicine intermediates.
As one of the subsidiaries of Jinghua Pharmaceutical Group Co.Ltd(002349) , senxuan pharmaceutical has always contributed a lot to the profits of Jinghua Pharmaceutical Group Co.Ltd(002349) .
According to the data, Jinghua Pharmaceutical Group Co.Ltd(002349) currently holds 309 million shares of senxuan medicine, accounting for 72.31% of the total share capital. According to the data of Jinghua Pharmaceutical Group Co.Ltd(002349) semi annual report in 2021, three of the company’s six subsidiaries lost money, and the other three zhongsenxuan pharmaceutical had a revenue of 263 million yuan and a net profit of 76.0113 million yuan, ranking first among the three subsidiaries.
Jinghua Pharmaceutical Group Co.Ltd(002349) 2021 semi annual report
In addition, the soaring share price of senxuan medicine also drove the share price of Jinghua Pharmaceutical Group Co.Ltd(002349) . At the same time, Jinghua Pharmaceutical Group Co.Ltd(002349) has also released relevant shareholder reduction plans recently. It is reported that on January 4, Zhou Yunzhong, the director and general manager of the company, planned to reduce the maximum holdings of 966000 shares, accounting for 0.12% of the total share capital.
In addition, according to the data, the share price of Jinghua Pharmaceutical Group Co.Ltd(002349) has risen to 22.45 yuan / share from 5.48 yuan / share in November 2021. As of the closing on February 10, its share price closed at 12.54 yuan / share, which is still 56.29 percentage points higher than the share price in November 2021.
